Ophthalmic Business News

Laura Enyedi, MD, Susan MacDonald, MD, and Cathleen McCabe, MD, talk with Michelle Cabrera, MD, Lauren Hock, MD, Olivia Killner, MD, and Brittni Scruggs, MD, PhD, on the topic of sexual harassment in the field of ophthalmology.

The European Medicines Agency accepted the marketing authorization application for avacincaptad pegol, according to a press release from Astellas Pharma.

An aflibercept biosimilar demonstrated positive results in the treatment of wet age-related macular degeneration in a phase 3 study, according to a press release from Sandoz.

Eyenovia has acquired the exclusive U.S. rights to distribute and sell APP13007, a potential treatment for inflammation and pain after ocular surgery, under an agreement with Formosa Pharmaceuticals, according to a press release.

The historic town of Lahaina on the island of Maui has been decimated by unprecedented wildfires that have left thousands homeless.

Two down, one to go.

The majority of patients with wet age-related macular degeneration who received aflibercept 8 mg maintained extended dosing intervals through 2 years in a pivotal trial, according to a press release from Regeneron.

The Greek philosopher Heraclitus is quoted as saying, “the only constant in life is change.”

HG004, a gene replacement therapy, received rare pediatric disease designation from the FDA for the treatment of inherited retinal diseases caused by RPE65 mutations, according to a press release from HuidaGene.

OCS-01 eye drops demonstrated positive topline results for the treatment of inflammation and pain after cataract surgery, according to a press release from Oculis.